ChromaDex Corporation (CDXC)
| Bid | 7.88 |
| Market Cap | 611.9M |
| Revenue (ttm) | 99.03M |
| Net Income (ttm) | 8.64M |
| EPS (ttm) | 0.11 |
| PE Ratio (ttm) | 71.55 |
| Forward PE | 44.15 |
| Analyst | Strong Buy |
| Ask | 7.89 |
| Volume | 541,672 |
| Avg. Volume (20D) | 815,353 |
| Open | 7.91 |
| Previous Close | 7.94 |
| Day's Range | 7.75 - 7.92 |
| 52-Week Range | 2.31 - 9.18 |
| Beta | 2.21 |
About CDXC
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-b...
Analyst Forecast
According to 3 analyst ratings, the average rating for CDXC stock is "Strong Buy." The 12-month stock price forecast is $8.1, which is an increase of 2.92% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
ChromaDex Capitalizes On Longevity Boom But Valuation Remains HighChromaDex Corporation shows strong revenue growth and profitability, driven by its NAD+ precursors and flagship product Niagen, despite high valuation and execution risks. Record-breaking financial pe...
1 month ago · businesswire.com
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 ResultsLOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 mil...
